We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

QGEN:NYSEQiagen N.V. analysis

Data as of Oct 18, 2026 - not real-time

Latest price
$46.13
Risk: medium
5/10Medium risk

Summary

Qiagen N.V. trades at $46.13, with its short-term moving averages stacked above the longer-term ones — a bullish trend structure. The last 30 days have gained 5.2%. Relative strength is 59.7 — neutral — and the MACD signal is bullish. The recent range runs from support at $41.94 up to resistance at $47.28.
On valuation the read is fair — earnings multiple of 23.4 versus a 31.5 sector average, below the peer group. Sell-side targets cluster 4.5% above the current quote. The 0.76% dividend yield looks covered by current payout levels.
Risk comes out at 5 of a possible 10, a moderate reading. With 30-day volatility of 33.5%, a beta of 0.44 and a maximum drawdown of 41.4%, position sizing matters here. The wider market backdrop reads extreme greed at 86 on the fear-greed composite.
The horizons line up on buy — conviction 6 out of 10.

Top market events

  • Fintel reports that on October 6, 2026, Barclays upgraded their outlook for Qiagen N.
  • Revenue reached USD 535.00 million in the second quarter of 2026. Qiagen stock costs EUR 37.59 on Oc
  • Qiagen N.V. NYSE:QGEN announced on August 10 that the U.S. FDA cleared its QIAstat-Dx BCID GPF Plus AMR Panel, marking...

Market outlook

Short term

< 1 year

Positive

Model confidence7/107 out of 10

Key factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 42.45
  • MACD momentum is positive

Medium term

1–3 years

Positive

Model confidence7/107 out of 10

Key factors

  • Short-term moving averages stacked above long-term ones
  • P/E of 23.4 versus sector average of 31.5
  • Trading above the 200-day average of 42.45

Long term

> 3 years

Positive

Model confidence6/106 out of 10

Key factors

  • P/E of 23.4 versus sector average of 31.5
  • Profit margin of 19.5% is healthy
  • Dividend yield of 0.76%

Key metrics

Financial health

Revenue Growth0.30%
Profit Margin19.49%
P/E Ratio23.4
ROE11.93%
ROA5.87%
Debt/Equity49.25
P/B Ratio2.8
Op. Cash Flow$654.5M
Free Cash Flow$372.9M
Industry P/E31.5

Technical analysis

TrendBullish
RSI59.7
Support$41.94
Resistance$47.28
MA 20$44.78
MA 50$43.81
MA 200$42.45
MACDBullish
VolumeDecreasing
Fear & Greed Index85.73

Valuation

Fair Value$18.00
Target Price$48.20
Upside/Downside4.49%
GradeFair
TypeBlend
Dividend Yield0.76%

Risk assessment

Beta0.44
Volatility33.50%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.